期刊
CELL STEM CELL
卷 22, 期 6, 页码 834-849出版社
CELL PRESS
DOI: 10.1016/j.stem.2018.05.013
关键词
-
资金
- National Eye Institute (NEI), Bethesda, MD, USA [NEI 01EY022079]
- Empire State Stem Cell Fund through New York State Department of Health [C028504]
- Regenerative Research Foundation
- Macular Vision Research Foundation [I01-BX002950]
- UK Medical Research Council
- European Research Council [ERC-2012-ADG_20120314]
- RP Fighting Blindness
- Carol and Dick Hertzberg Fund
- Richard Annesser Fund
- MRC [MR/J004553/1, MR/M007871/1] Funding Source: UKRI
Ocular regenerative therapies are on track to revolutionize treatment of numerous blinding disorders, including corneal disease, cataract, glaucoma, retinitis pigmentosa, and age-related macular degeneration. A variety of transplantable products, delivered as cell suspensions or as preformed 3D structures combining cells and natural or artificial substrates, are in the pipeline. Here we review the status of clinical and preclinical studies for stem cell-based repair, covering key eye tissues from front to back, from cornea to retina, and including bioengineering approaches that advance cell product manufacturing. While recognizing the challenges, we look forward to a deep portfolio of sight-restoring, stem cell-based medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据